Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 11/20 | 1.00 |
| ▸ | MAOB | P27338 | 2/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | APP | P05067 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL700761 | 1.00 | NFE2L2 (1.00) | NFE2L2MAOBCYP19A1MAOAAPP | |
| SCHEMBL700760 | 1.00 | NFE2L2 (1.00) | NFE2L2MAOBCYP19A1MAOAAPP | |
| SCHEMBL18867936 | 1.00 | NFE2L2 (1.00) | NFE2L2MAOBCYP19A1MAOAAPP | |
| SCHEMBL13766558 | 0.88 | NFE2L2 (0.78) | NFE2L2APPPTGS1 | |
| SCHEMBL13766470 | 0.88 | NFE2L2 (0.78) | NFE2L2APPPTGS1 | |
| SCHEMBL700052 | 0.88 | NFE2L2 (0.78) | NFE2L2APPPTGS1 | |
| SCHEMBL700051 | 0.88 | NFE2L2 (0.78) | NFE2L2APPPTGS1 | |
| SCHEMBL22468800 | 0.88 | NFE2L2 (0.78) | NFE2L2APPPTGS1 | |
| SCHEMBL11547655 | 0.85 | NFE2L2 (0.72) | NFE2L2MAOBCYP19A1MAOARELA | |
| SCHEMBL44504 | 0.85 | NFE2L2 (0.72) | NFE2L2MAOBCYP19A1MAOARELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1043793-B1 | Secondary battery | MATSUSHITA ELECTRIC INDUSTRIAL CO LTD (JP) | 2008-04-02 | — | — | EP | claimed |
| US-6303250-B1 | BATTERIES USING NONAQUEOUS ELECTROLYTIC SOLUTION; HIGH TEMPERATURE STORAGE | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 2001-10-16 | — | — | US | claimed |
| EP-1043793-A2 | Secondary battery | Matsushita Electric Industrial Co., Ltd. (JP) | 2000-10-11 | — | — | EP | claimed |
| US-11858889-B2 | Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| EP-2810198-B1 | ANTI-INVASIVE COMPOUNDS | UNIV GENT (BE) | 2023-07-12 | — | — | EP | disclosed |
| WO-2020198464-A1 | HIGHLY SELECTIVE ELECTROCHEMICAL HYDROGENATION OF ALKYNES | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2020-10-01 | — | — | WO | disclosed |
| US-9290427-B2 | Anti-invasive compounds | UNIVERSITEIT GENT (BE) | 2016-03-22 | — | — | US | disclosed |
| US-8980954-B2 | Substituted cis- and trans-stilbenes as therapeutic agents | STC.UNM (US) | 2015-03-17 | — | — | US | disclosed |
| US-20150011620-A1 | ANTI-INVASIVE COMPOUNDS | UNIVERSITEIT GENT (BE) | 2015-01-08 | — | — | US | disclosed |
| EP-2810198-A1 | ANTI-INVASIVE COMPOUNDS | Universiteit Gent (BE) | 2014-12-10 | — | — | EP | disclosed |
| WO-2013113722-A1 | ANTI-INVASIVE COMPOUNDS | UNIVERSITEIT GENT (BE) | 2013-08-08 | — | — | WO | disclosed |
| EP-1043793-B1 | Secondary battery | MATSUSHITA ELECTRIC INDUSTRIAL CO LTD (JP) | 2008-04-02 | — | — | EP | disclosed |
| US-20070249647-A1 | Substituted CIS- and trans-stilbenes as therapeutic agents | REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2007-10-25 | — | — | US | disclosed |
| US-6303250-B1 | BATTERIES USING NONAQUEOUS ELECTROLYTIC SOLUTION; HIGH TEMPERATURE STORAGE | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 2001-10-16 | — | — | US | disclosed |
| JP-2000299125-A | NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | MATSUSHITA ELECTRIC IND CO LTD | 2000-10-24 | — | — | JP | disclosed |
| EP-1043793-A2 | Secondary battery | Matsushita Electric Industrial Co., Ltd. (JP) | 2000-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249647-A1 | Substituted CIS- and trans-stilbenes as therapeutic agents | TGFB1, VHL, TMSB10 | NFE2L2 68/4885MAOB 1359/4885CYP19A1 143/4885 |
| US-11858889-B2 | Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease | ADM2, DDAH1, BHMT | NFE2L2 713/4885MAOB 544/4885CYP19A1 445/4885 |
| US-20150011620-A1 | ANTI-INVASIVE COMPOUNDS | MMP3, MMP10, MIF | NFE2L2 1215/4885MAOB 4150/4885CYP19A1 2401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.